Survodutide: Phase 3 weight-loss results and liver-disease evidence
Read survodutide’s SYNCHRONIZE Phase 3 results, gastrointestinal safety findings and separate MASH research with clear evidence limits.
Search explainers, questions, and medicine profiles.
Every published article, newest first. Reporting, explainers, and practical guides on weight and metabolic health.
Read survodutide’s SYNCHRONIZE Phase 3 results, gastrointestinal safety findings and separate MASH research with clear evidence limits.
Use resistance activity to support daily function while managing weight, with a starting point matched to your ability.
What the sleep-extension trial means: the 270-calorie comparison, two-week limits, objective intake methods and a practical sleep observation sheet.
Read semaglutide’s STEP and SELECT results, product-specific approvals, safety warnings and weight-maintenance evidence.
Retatrutide’s Phase 2 and Phase 3 weight-loss evidence, trial limitations, safety questions and verified US approval status, explained.
Work through SELECT event counts, absolute differences, and hazard ratios, then use a five-line checklist to assess cardiovascular risk headlines.
Read the population, comparator, duration, analysis, and harms before deciding what a weight-loss headline really means.
Protein matters, but more is not a universal solution. Pair food planning with activity, function, and an individualized target.
Two trial populations, one label table and the questions that keep an oral-treatment headline in context.